Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.

Krämer AL, Riederer A, Fracassi F, Boretti FS, Sieber-Ruckstuhl NS, Lutz TA, Contiero B, Zini E, Reusch CE

Journal of veterinary internal medicine1 Oct 2020Cited by 18 (Europe PMC)

PMID33001499PMCIDPMC7694851DOI10.1111/jvim.15915PepBankPUB-33001499

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic cats, glycemic variability with exenatide was lower at week 6 than week 1.
In plain wordsIn cats with diabetes, blood sugar variability with exenatide was lower at week 6 than week 1.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV at week 6 versus week 1
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Week 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
200 μg/kg once weekly · SCAs given in this study (cat).
Source sentences
Summary
In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93])
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
Report a problemFND-3300149901
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic cats, glycemic variability with exenatide was lower at week 10 than week 1.
In plain wordsIn cats with diabetes, blood sugar variability with exenatide was lower at week 10 than week 1.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV at week 10 versus week 1
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Week 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
200 μg/kg once weekly · SCAs given in this study (cat).
Source sentences
Summary
In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93])
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
Report a problemFND-3300149902
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic cats, glycemic variability with exenatide was lower at week 16 than week 1.
In plain wordsIn cats with diabetes, blood sugar variability with exenatide was lower at week 16 than week 1.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV at week 16 versus week 1
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Week 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
200 μg/kg once weekly · SCAs given in this study (cat).
Source sentences
Summary
In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93])
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
Report a problemFND-3300149903
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic cats, exenatide reduced glycemic variability versus placebo at week 6.
In plain wordsIn cats with diabetes, exenatide reduced blood sugar variability versus placebo at week 6.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV at week 6 versus placebo
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
200 μg/kg once weekly · SCAs given in this study (cat).
Source sentences
Summary
and lower compared to placebo at week 6 (3.29 mmol/L [1.95-4.63]; P = .04) and week 10 (4.34 mmol/L [2.43-6.24]; P < .000).
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
Report a problemFND-3300149904
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic cats, exenatide reduced glycemic variability versus placebo at week 10.
In plain wordsIn cats with diabetes, exenatide reduced blood sugar variability versus placebo at week 10.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV at week 10 versus placebo
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
200 μg/kg once weekly · SCAs given in this study (cat).
Source sentences
Summary
and lower compared to placebo at week 6 (3.29 mmol/L [1.95-4.63]; P = .04) and week 10 (4.34 mmol/L [2.43-6.24]; P < .000).
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
Report a problemFND-3300149905

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic cats from the exenatide trial, remission was linked to lower glycemic variability at week 6.
In plain wordsIn cats with diabetes from the exenatide trial, remission was linked to lower blood sugar variability than no remission.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGV by remission status
Study
catn: not reported in source
Newly diagnosed spontaneous diabetes mellitus
Comparator
Cats without remission
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Cats achieving remission (1.21 mmol/L [0.23-2.19]) had lower GV compared to those without remission (2.96 mmol/L [1.97-3.96]; P = .01) at week 6.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective study.
Summary · context
Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3300149906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.